R&D News | pharmaphorum

News

Takeda CEO succession confirmed as Weber plans retirement

Takeda's long-serving chief executive Christophe Weber has said he will retire next year, after 12 years at the Japanese drugmaker.

News

Troubled 23andMe is exploring a sale of the business

Genetic testing specialist 23andMe has launched a strategic review that could result in a sale of the company.

News

AI in medical imaging company Quibim raises $50m

Quibim has raised $50 million in first-round financing to support the rollout of its AI biomarkers for use in the analysis of medical imaging.

News

Sage rejects Biogen takeover and launches review

Sage Therapeutics has unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company.

News

Veru shares plunge despite positive data in obesity trial

Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.

News

Martin Olin has been named chief executive of the UK start-up

UK biotech Swarm lands with a T-cell therapy mission

UK firm Swarm Oncology launches with a T-cell therapy platform to treat solid tumours, with a Resolution Therapeutics co-founder in the pilot seat.

Takeda CEO succession confirmed as Weber plans retirement

Troubled 23andMe is exploring a sale of the business

AI in medical imaging company Quibim raises $50m

Sage rejects Biogen takeover and launches review

Veru shares plunge despite positive data in obesity trial

UK biotech Swarm lands with a T-cell therapy mission

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks